tradingkey.logo
๎™ผ
tradingkey.logo
๎™๊ฒ€์ƒ‰
๎™

Sanofi SA

SNY
๎˜ญ๊ด€์‹ฌ ๋ชฉ๋ก์— ์ถ”๊ฐ€
44.260USD
-0.070-0.16%
์ข…๊ฐ€ย 09-04 16:00๏ผˆET๏ผ‰
105.99B์‹œ๊ฐ€์ด์•ก
12.30P/E TTM

์ž์„ธํ•œ ๋‚ด์šฉ์€ Sanofi SA ํšŒ์‚ฌ

Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofiโ€™s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Companyโ€™s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.

Sanofi SA ํ”„๋กœํ•„

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ SNY
ํšŒ์‚ฌ ์ด๋ฆ„Sanofi SA
์ƒ์žฅ์ผJul 01, 2002
CEOHudson (Paul)
์ง์› ์ˆ˜84587
์œ ํ˜•Depository Receipt
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒJul 01
์ฃผ์†Œ46 Avenue de la Grande Armee
๋„์‹œPARIS
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†ŒNASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐ€France
์šฐํŽธ ๋ฒˆํ˜ธ75017
์ „ํ™”33153774000
์›น์‚ฌ์ดํŠธhttps://www.sanofi.com/
์ข…๋ชฉ ์ฝ”๋“œ SNY
์ƒ์žฅ์ผJul 01, 2002
CEOHudson (Paul)

Sanofi SA์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Mr. Olivier Charmeil
Mr. Olivier Charmeil
Executive Vice President - General Medicines, Member of the Executive Committee
Executive Vice President - General Medicines, Member of the Executive Committee
--
--
Dr. Belen Garijo, M.D.
Dr. Belen Garijo, M.D.
Chief Executive Officer, Member of the Executive Committee, Director
Chief Executive Officer, Member of the Executive Committee, Director
--
--
Ms. Fabienne Lecorvaisier
Ms. Fabienne Lecorvaisier
Independent Director
Independent Director
--
--
Mr. Patrick Kron
Mr. Patrick Kron
Independent Director
Independent Director
--
--
Mr. Christophe Babule
Mr. Christophe Babule
Director
Director
--
--
Mr. Paul Hudson, Ph.D.
Mr. Paul Hudson, Ph.D.
Chief Executive Officer, Executive Director, Member of the Executive Committee
Chief Executive Officer, Executive Director, Member of the Executive Committee
--
--
Ms. Rachel Duan
Ms. Rachel Duan
Independent Director
Independent Director
--
--
Ms. Lise Kingo
Ms. Lise Kingo
Independent Director
Independent Director
--
--
Ms. Natalie Bickford
Ms. Natalie Bickford
Chief People Officer, Executive Vice President, Member of the Executive Committee
Chief People Officer, Executive Vice President, Member of the Executive Committee
--
--
Ms. Julie Van Ongevalle
Ms. Julie Van Ongevalle
Executive Vice President - Consumer Healthcare, Member of the Executive Committee
Executive Vice President - Consumer Healthcare, Member of the Executive Committee
--
--
๋” ๋ณด๊ธฐ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Mr. Olivier Charmeil
Mr. Olivier Charmeil
Executive Vice President - General Medicines, Member of the Executive Committee
Executive Vice President - General Medicines, Member of the Executive Committee
--
--
Dr. Belen Garijo, M.D.
Dr. Belen Garijo, M.D.
Chief Executive Officer, Member of the Executive Committee, Director
Chief Executive Officer, Member of the Executive Committee, Director
--
--
Ms. Fabienne Lecorvaisier
Ms. Fabienne Lecorvaisier
Independent Director
Independent Director
--
--
Mr. Patrick Kron
Mr. Patrick Kron
Independent Director
Independent Director
--
--
Mr. Christophe Babule
Mr. Christophe Babule
Director
Director
--
--
Mr. Paul Hudson, Ph.D.
Mr. Paul Hudson, Ph.D.
Chief Executive Officer, Executive Director, Member of the Executive Committee
Chief Executive Officer, Executive Director, Member of the Executive Committee
--
--

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

Sanofi SA์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋ˆ„๊ตฌ์ธ๊ฐ€์š”?

๎™Œ
Sanofi SA์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค: Mr. Olivier Charmeil

Sanofi SA(SNY)์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ๋ช‡ ๊ฐœ์ž…๋‹ˆ๊นŒ?

๎™Œ
2026Q1 ๊ธฐ์ค€์œผ๋กœ, Sanofi SA์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ์ด 1330๊ณณ์ด๋ฉฐ, ์ด๋“ค์ด ๋ณด์œ ํ•œ ์ฃผ์‹์˜ ์ด ๊ฐ€์น˜๋Š” ์•ฝ 225.52M๋กœ ์ „์ฒด ๋ฐœํ–‰ ์ฃผ์‹์˜ 9.34%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค. ์ด๋Š” 2025Q4 ๋Œ€๋น„ -36323619.00 ์ฆ๊ฐ€ํ•œ ์ˆ˜์น˜์ž…๋‹ˆ๋‹ค.
tradingkey.logo
์œ„ํ—˜ ๊ฒฝ๊ณ : ์ €ํฌ ์›น์‚ฌ์ดํŠธ์™€ ๋ชจ๋ฐ”์ผ ์•ฑ์€ ํŠน์ • ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ผ๋ฐ˜์ ์ธ ์ •๋ณด๋งŒ์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. Finsights๋Š” ์žฌ์ •์  ์กฐ์–ธ์ด๋‚˜ ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜์ง€ ์•Š์œผ๋ฉฐ, ์ด๋Ÿฌํ•œ ์ •๋ณด ์ œ๊ณต์ด Finsights๊ฐ€ ๊ธˆ์œต ์กฐ์–ธ์ด๋‚˜ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜๋Š” ๊ฒƒ์œผ๋กœ ํ•ด์„๋˜์–ด์„œ๋Š” ์•ˆ ๋ฉ๋‹ˆ๋‹ค.
ํˆฌ์ž ์ƒํ’ˆ์€ ํˆฌ์ž ์›๊ธˆ ์†์‹ค์„ ํฌํ•จํ•œ ์ƒ๋‹นํ•œ ํˆฌ์ž ์œ„ํ—˜์— ๋…ธ์ถœ๋˜์–ด ์žˆ์œผ๋ฉฐ, ๋ชจ๋“  ์‚ฌ๋žŒ์—๊ฒŒ ์ ํ•ฉํ•˜์ง€ ์•Š์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ํˆฌ์ž ์ƒํ’ˆ์˜ ๊ณผ๊ฑฐ ์„ฑ๊ณผ๋Š” ๋ฏธ๋ž˜ ์„ฑ๊ณผ๋ฅผ ๋ณด์žฅํ•˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.
Finsights๋Š” ์ œ3์ž ๊ด‘๊ณ ์ฃผ๋‚˜ ์ œํœด์‚ฌ๊ฐ€ ์ €ํฌ ์›น์‚ฌ์ดํŠธ๋‚˜ ๋ชจ๋ฐ”์ผ ์•ฑ ๋˜๋Š” ๊ทธ ์ผ๋ถ€์— ๊ด‘๊ณ ๋ฅผ ๊ฒŒ์žฌํ•˜๊ฑฐ๋‚˜ ์ „๋‹ฌํ•  ์ˆ˜ ์žˆ๋„๋ก ํ—ˆ์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ, ์‚ฌ์šฉ์ž๊ฐ€ ๊ด‘๊ณ ์™€ ์ƒํ˜ธ์ž‘์šฉํ•˜๋Š” ๋ฐฉ์‹์— ๋”ฐ๋ผ ์ด๋“ค๋กœ๋ถ€ํ„ฐ ๋ณด์ƒ์„ ๋ฐ›์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
ยฉ ์ €์ž‘๊ถŒ: FINSIGHTS MEDIA PTE. LTD. ๋ชจ๋“  ๊ถŒ๋ฆฌ ๋ณด์œ